AI reads heart signals to simplify cancer drug monitoring

NCT ID NCT05623397

Completed Knowledge-focused Sponsor: CMC Ambroise Paré Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether an artificial intelligence (AI) model can accurately measure heart rhythm changes (QTc) from ECGs in 70 breast cancer patients starting the drug ribociclib. The goal was to see if simpler ECG devices could work as well as standard 12-lead machines when analyzed by AI. The findings could make heart monitoring easier and more accessible during cancer treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER RIBOCICLIB

Contacts and locations

Locations

CIC - Hôpitaux Universitaires Pitié Salpêtrière, Paris, FRANCE

Paris, 75651, France
Groupe Ambroise Paré, Hartmann

Neuilly-sur-Seine, 92200, France
Hôpital Tenon

Paris, 75020, France
Institut Gustave Roussy

Villejuif, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.